
Semax
Research Peptide | Lyophilized Powder | Batch Tested
For laboratory research use only. Not for human or animal consumption. Insulated shipping · Styrofoam box available.
Product Overview
Semax is a synthetic heptapeptide derived from the ACTH(4-10) fragment, engineered with a Pro-Gly-Pro tail for stability. It is widely studied as a neuroprotective and nootropic research peptide with no hormonal (corticotropic) activity.
| Test | Result | Status |
|---|---|---|
| Purity | 99.3% | Passed ✓ |
| Test | Result | Status |
|---|---|---|
| Purity | 99.0% | Passed ✓ |
Research Information
Semax is investigated for its effects on the expression of BDNF and NGF, dopaminergic and serotonergic signaling, and neuroprotection under ischemic and oxidative-stress conditions in animal and cell models of cognition and brain injury. Supplied strictly for in-vitro and laboratory research use only — not for human or animal consumption.
Semax Research & Studies
What is Semax?
Semax is a synthetic heptapeptide structurally derived from the ACTH(4-10) fragment and modified with a C-terminal Pro-Gly-Pro sequence to enhance metabolic stability in experimental systems. It lacks measurable corticotropic activity and is examined strictly as a research tool in cellular and animal models. Laboratory investigations focus on its interactions with neurotrophic and monoaminergic pathways under controlled conditions. The compound is supplied exclusively for in-vitro and non-clinical laboratory research.
Mechanism of Action
In cell-culture and rodent-brain preparations, Semax is studied for its capacity to modulate expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Research models also explore effects on dopaminergic and serotonergic signaling cascades as well as downstream transcriptional responses. These actions are investigated under conditions of oxidative challenge or simulated ischemia to map pathway engagement. Observed molecular changes remain confined to experimental readouts and do not extend to any applied context.
Primary Areas of Research
Primary research domains include neuroprotection assays employing ischemic and oxidative-stress models in neuronal cultures and laboratory animals. Additional studies examine cognitive-performance endpoints in maze and recognition paradigms, as well as alterations in monoamine turnover within discrete brain regions. Investigators further evaluate gene-expression profiles related to synaptic plasticity and stress-response pathways. All work is conducted under research-use-only protocols using defined experimental systems.
Key Research Findings
Published laboratory data report elevated BDNF and NGF transcript levels following Semax exposure in selected neuronal cell lines and rodent brain tissue. Separate studies document shifts in dopamine and serotonin metabolite ratios under controlled stress paradigms. Neuroprotective endpoints such as reduced markers of oxidative damage have been quantified in ischemia-mimetic models. These findings are model-specific and serve solely to characterize peptide activity in vitro and in non-clinical systems.
Research Handling & Considerations
Semax is typically reconstituted in sterile aqueous buffers suitable for cell-culture or tissue-homogenate experiments and stored under recommended cold-chain conditions to preserve peptide integrity. Investigators must verify purity and concentration by analytical methods prior to use in any assay. Standard laboratory safety practices apply, including appropriate personal protective equipment and waste disposal. The material is intended solely for controlled research environments and is not for any form of administration.
Frequently Asked Questions
Semax consists of the ACTH(4-10) sequence extended by a Pro-Gly-Pro motif that improves resistance to enzymatic degradation in experimental media, allowing longer observation windows in cell and tissue models.
Explore Other High-Purity Peptides

Epithalon

DSIP

Selank
